Caladrius Biosciences Inc (NASDAQ:CLBS) Receives $10.42 Consensus Target Price from Brokerages

Shares of Caladrius Biosciences Inc (NASDAQ:CLBS) have been assigned a consensus rating of “Buy” from the six ratings firms that are covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $10.42.

Several brokerages recently issued reports on CLBS. Zacks Investment Research lowered shares of Caladrius Biosciences from a “hold” rating to a “sell” rating in a report on Monday, May 20th. Chardan Capital reissued a “buy” rating and set a $6.00 price objective on shares of Caladrius Biosciences in a report on Sunday, May 12th. ValuEngine lowered shares of Caladrius Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Dawson James reissued a “buy” rating on shares of Caladrius Biosciences in a report on Wednesday, February 27th. Finally, WBB Securities began coverage on shares of Caladrius Biosciences in a report on Tuesday, May 14th. They set a “speculative buy” rating and a $6.75 price objective on the stock.

A number of hedge funds have recently modified their holdings of the stock. Morgan Stanley grew its holdings in Caladrius Biosciences by 218.6% in the first quarter. Morgan Stanley now owns 6,996 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 4,800 shares during the last quarter. Wesbanco Bank Inc. purchased a new position in Caladrius Biosciences in the first quarter worth $36,000. Summit Trail Advisors LLC purchased a new position in Caladrius Biosciences in the first quarter worth $64,000. Renaissance Technologies LLC grew its holdings in Caladrius Biosciences by 6.9% in the first quarter. Renaissance Technologies LLC now owns 315,348 shares of the biotechnology company’s stock worth $1,142,000 after purchasing an additional 20,253 shares during the last quarter. Finally, Vanguard Group Inc grew its holdings in Caladrius Biosciences by 2.9% in the third quarter. Vanguard Group Inc now owns 202,568 shares of the biotechnology company’s stock worth $1,196,000 after purchasing an additional 5,700 shares during the last quarter. 7.59% of the stock is currently owned by institutional investors.

Shares of NASDAQ:CLBS traded up $0.02 during trading on Friday, reaching $2.93. 380 shares of the company were exchanged, compared to its average volume of 21,269. Caladrius Biosciences has a 12-month low of $2.65 and a 12-month high of $11.65.

Caladrius Biosciences (NASDAQ:CLBS) last issued its earnings results on Thursday, May 9th. The biotechnology company reported ($0.44) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.05). Sell-side analysts anticipate that Caladrius Biosciences will post -1.65 earnings per share for the current year.

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.

Featured Article: How Do Mutual Funds Work?

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.